Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Advances in Therapy
|
July 24, 2010
Telaprevir: a new hope in the treatment of chronic hepatitis C?
Andrew J Fowell, Kathryn L Nash
Digestive Diseases (Basel, Switzerland)
|
May 16, 2006
Emerging therapies for liver fibrosis
Andrew J Fowell, John P Iredale
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 24, 2008
Renal hepatitis C in the absence of detectable serum or hepatic virus
Andrew J Fowell, Nicholas Sheron, William M C Rosenberg
Frontline Gastroenterology
|
March 15, 2024
Novel, nurse-led early postdischarge clinic is associated with fewer readmissions and lower mortality following hospitalisation with decompensated cirrhosis
Benjamin Giles, Kirsty Fancey, Karen Gamble, et al.
Frontline Gastroenterology
|
February 22, 2021
Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease
Andrew J Fowell, Kirsty Fancey, Karen Gamble, et al.
Biochemical and Biophysical Research Communications
|
February 9, 2011
Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation
Andrew J Fowell, Jane E Collins, Dale R Duncombe, et al.
Gastroenterology
|
January 29, 2020
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
Eleonora Scorletti, Paul R Afolabi, Elizabeth A Miles, et al.
Nature Communications
|
March 3, 2023
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans
Kodihalli C Ravindra, Vishal S Vaidya, Zhenyu Wang, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Advances in Therapy
|
July 24, 2010
Telaprevir: a new hope in the treatment of chronic hepatitis C?
Andrew J Fowell, Kathryn L Nash
Digestive Diseases (Basel, Switzerland)
|
May 16, 2006
Emerging therapies for liver fibrosis
Andrew J Fowell, John P Iredale
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 24, 2008
Renal hepatitis C in the absence of detectable serum or hepatic virus
Andrew J Fowell, Nicholas Sheron, William M C Rosenberg
Frontline Gastroenterology
|
March 15, 2024
Novel, nurse-led early postdischarge clinic is associated with fewer readmissions and lower mortality following hospitalisation with decompensated cirrhosis
Benjamin Giles, Kirsty Fancey, Karen Gamble, et al.
Frontline Gastroenterology
|
February 22, 2021
Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease
Andrew J Fowell, Kirsty Fancey, Karen Gamble, et al.
Biochemical and Biophysical Research Communications
|
February 9, 2011
Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation
Andrew J Fowell, Jane E Collins, Dale R Duncombe, et al.
Gastroenterology
|
January 29, 2020
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
Eleonora Scorletti, Paul R Afolabi, Elizabeth A Miles, et al.
Nature Communications
|
March 3, 2023
Tandem mass tag-based quantitative proteomic profiling identifies candidate serum biomarkers of drug-induced liver injury in humans
Kodihalli C Ravindra, Vishal S Vaidya, Zhenyu Wang, et al.
Page
of 1